Business
ONT opens user conference, rich science programme
ONT opens user conference, rich science programme.
About this update from Oxford Nanopore Technologies Plc
[{"type":"text","content":"\n \n \n \n Oxford Nanopore's London Calling conference opens; amongst a breadth of ground-breaking research, increasing attention on human and cancer genomics\n \n \n \n \n Conference presentations set to highlight the utility of comprehensive genomic analysis using nanopore sequencing for novel discoveries in human genetics, cancer research, conservation, pathogen genomics and more\n \n \n \n \n Thursday 19th May\n \n \n \n The annual London Calling genomics conference, hosted by Oxford Nanopore, starts today, featuring more than 80 scientific talks across a range of disciplines, with thousands of scientists expected to attend either in person or online.\n \n \n Increasing numbers of researchers are applying Oxford Nanopore's sequencing technology to human and cancer genomics to make new discoveries. These novel insights are fueling basic and translational research and will have potential utility in the future in healthcare. Until\n recently human and cancer genomic research had been more focused on the detection of single nucleotide polymorphisms (SNPs) and indels (inserted or deleted bases), however now nanopore sequencing is supporting the discovery of the genetic underpinnings of disease, enabling functional genomics and novel biomarker discovery. Additionally, with nanopore sequencing's capabilities of simultaneous genomic and epigenomic analysis of native DNA, it is also now possible to accurately and simultaneously detect structural variants (SVs), copy number variants (CNVs) and methylation at haplotype-resolved level.\n \n \n Research presented this week demonstrates the scientific value of characterising this richer information and is signalling an expansion in the types of analysis being performed in human genomic research, especially for cancer.\n Nanopore sequencing can provide the most comprehensive insight into the human genome in health and in disease states, such as cancer, to:\n \n \n ·\n Resolve variants and epigenetic modifications across the entire genome\n \n \n ·\n Target large panels or single genes, without PCR\n \n \n ·\n Detect known and novel full-length transcripts - up to single-cell resolution.\n \n \n \n Gordon Sanghera, CEO Oxford Nanopore Technologies, commented:\n \n \n \n \n \n \n \n \n \n \"We're excited to welcome scientific researchers to London from 100 countries this year, present...